Maximum Tolerated Dose

"Maximum Tolerated Dose" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus, MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure, which enables searching at various levels of specificity.

MeSH information

Definition | Details | More General Concepts | Related Concepts | More Specific Concepts

The highest dose of a biologically active agent given during a chronic study that will not reduce longevity from effects other than carcinogenicity. (from Lewis Dictionary of Toxicology, 1st ed)

Descriptor ID	D020714
MeSH Number(s)	E05.940.481 G07.690.936.625
Concept/Terms	Maximum Tolerated Dose Maximum Tolerated Dose Dose, Maximum Tolerated Doses, Maximum Tolerated Maximum Tolerated Doses Tolerated Dose, Maximum Tolerated Doses, Maximum Maximally Tolerated Dose Dose, Maximally Tolerated Doses, Maximally Tolerated Maximally Tolerated Doses Tolerated Dose, Maximally Tolerated Doses, Maximally Maximal Tolerated Dose Dose, Maximal Tolerated Doses, Maximal Tolerated Maximal Tolerated Doses Tolerated Dose, Maximal Tolerated Doses, Maximal

Below are MeSH descriptors whose meaning is more general than "Maximum Tolerated Dose".

Analytical, Diagnostic and Therapeutic Techniques and Equipment [E]
Investigative Techniques [E05]
Toxicity Tests [E05.940]
Maximum Tolerated Dose [E05.940.481]
Biological Sciences [G]
Physiological Phenomena [G07]
Pharmacological and Toxicological Phenomena [G07.690]
Toxicological Phenomena [G07.690.936]
Maximum Tolerated Dose [G07.690.936.625]

Below are MeSH descriptors whose meaning is related to "Maximum Tolerated Dose".

Below are MeSH descriptors whose meaning is more specific than "Maximum Tolerated Dose".

publications

Timeline | Most Recent

This graph shows the total number of publications written about "Maximum Tolerated Dose" by people in this website by year, and whether "Maximum Tolerated Dose" was a major or minor topic of these publications.

Bar chart showing 8 publications over 7 distinct years, with a maximum of 2 publications in 2010

To see the data from this visualization as text, click here.

Year	Major Topic	Minor Topic	Total
2004	0	1	1
2010	0	2	2
2011	0	1	1
2013	0	1	1
2015	0	1	1
2017	1	0	1
2018	0	1	1

Below are the most recent publications written about "Maximum Tolerated Dose" by people in Profiles.

Akingbola TS, Tayo BO, Ezekekwu CA, Sonubi O, Zhang X, Saraf SL, Molokie R, Hsu LL, Han J, Cooper RS, Gordeuk VR. "Maximum tolerated dose" vs "fixed low-dose" hydroxyurea for treatment of adults with sickle cell anemia. Am J Hematol. 2019 04; 94(4):E112-E115.

View in: PubMed
Italiano A, Soria JC, Toulmonde M, Michot JM, Lucchesi C, Varga A, Coindre JM, Blakemore SJ, Clawson A, Suttle B, McDonald AA, Woodruff M, Ribich S, Hedrick E, Keilhack H, Thomson B, Owa T, Copeland RA, Ho PTC, Ribrag V. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study. Lancet Oncol. 2018 05; 19(5):649-659.

View in: PubMed
Koopmeiners JS, Wey A. The Randomized CRM: An Approach to Overcoming the Long-Memory Property of the CRM. J Biopharm Stat. 2017; 27(6):1028-1042.

View in: PubMed
Han J, Bhat S, Gowhari M, Gordeuk VR, Saraf SL. Impact of a Clinical Pharmacy Service on the Management of Patients in a Sickle Cell Disease Outpatient Center. Pharmacotherapy. 2016 11; 36(11):1166-1172.

View in: PubMed
Fitzhugh CD, Hsieh MM, Allen D, Coles WA, Seamon C, Ring M, Zhao X, Minniti CP, Rodgers GP, Schechter AN, Tisdale JF, Taylor JG. Hydroxyurea-Increased Fetal Hemoglobin Is Associated with Less Organ Damage and Longer Survival in Adults with Sickle Cell Anemia. PLoS One. 2015; 10(11):e0141706.

View in: PubMed
Horsley L, Cummings J, Middleton M, Ward T, Backen A, Clamp A, Dawson M, Farmer H, Fisher N, Halbert G, Halford S, Harris A, Hasan J, Hogg P, Kumaran G, Little R, Parker GJ, Potter P, Saunders M, Roberts C, Shaw D, Smith N, Smythe J, Taylor A, Turner H, Watson Y, Dive C, Jayson GC. A phase 1 trial of intravenous 4-(N-(S-glutathionylacetyl)amino) phenylarsenoxide (GSAO) in patients with advanced solid tumours. Cancer Chemother Pharmacol. 2013 Dec; 72(6):1343-52.

View in: PubMed
Emmenegger U, Francia G, Chow A, Shaked Y, Kouri A, Man S, Kerbel RS. Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide. Neoplasia. 2011 Jan; 13(1):40-8.

View in: PubMed
Hsia SH. Insulin glargine compared to NPH among insulin-na?ve, U.S. inner city, ethnic minority type 2 diabetic patients. Diabetes Res Clin Pract. 2011 Mar; 91(3):293-9.

View in: PubMed
Boateng CA, Eyunni SV, Zhu XY, Etukala JR, Bricker BA, Ashfaq MK, Jacob MR, Khan SI, Walker LA, Ablordeppey SY. Benzothieno[3,2-b]quinolinium and 3-(phenylthio)quinolinium compounds: Synthesis and evaluation against opportunistic fungal pathogens. Bioorg Med Chem. 2011 Jan 01; 19(1):458-70.

View in: PubMed
Emmenegger U, Man S, Shaked Y, Francia G, Wong JW, Hicklin DJ, Kerbel RS. A comparative analysis of low-dose metronomic cyclophosphamide reveals absent or low-grade toxicity on tissues highly sensitive to the toxic effects of maximum tolerated dose regimens. Cancer Res. 2004 Jun 01; 64(11):3994-4000.

View in: PubMed

People

Explore

Similar Concepts

Top Journals